文献速递眼底病与葡萄膜炎

沉默lncRNA HOTAIR的眼药水:糖尿病相关视网膜失调与功能障碍的潜在治疗

Silencing of lncRNA HOTAIR Using Eyedrops as a Potential Treatment for Diabetes-Associated Retinal Dysregulation and Dysfunction.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2026-01-01

本研究探索利用偶联N-乙酰半乳糖胺(GalNAc)的siRNA靶向沉默长链非编码RNA HOTAIR,以预防糖尿病相关视网膜病变。体外实验显示GalNAc修饰的siHOTAIR可有效进入人视网膜内皮细胞并抑制葡萄糖诱导的内皮功能障碍;体内局部给药后siRNA定位于视网膜,预防糖尿病诱导的视网膜病理改变,疗效与玻璃体腔注射相当。结论认为该策略不仅抑制VEGF还靶向HOTAIR调控的其他致病介质,且通过非侵入性局部给药实现,有望成为优于抗VEGF单药治疗的糖尿病视网膜病变新方法。

要点

  • GalNAc修饰的siHOTAIR体外可进入人视网膜内皮细胞并抑制葡萄糖诱导的内皮功能障碍。
  • 局部递送后GalNAc-siRNA定位于视网膜,预防糖尿病诱导的视网膜病理改变。
  • 其疗效与玻璃体腔注射相当,且为非侵入性给药,可规避玻璃体腔注射需求。

核心结论

  • GalNAc修饰的siHOTAIR是潜在治疗策略,不仅抑制VEGF还靶向HOTAIR调控的其他致病介质,可能比抗VEGF单药治疗更有效。
  • 该策略通过非侵入性局部递送实现,规避当前治疗所需的玻璃体腔注射,进一步开发后可能成为治疗糖尿病视网膜病变的更好方法。

研究设计与样本

  • 研究在体外使用人视网膜内皮细胞评估GalNAc修饰的siHOTAIR,并在体内采用多种模型进行评估。
  • 从RNA、蛋白质和功能水平评估GalNAc修饰的siHOTAIR的效果。

主要发现

  • GalNAc修饰的siHOTAIR体外有效进入视网膜内皮细胞,并通过阻断包括VEGF-A在内的多种因子抑制葡萄糖诱导的内皮功能障碍。
  • GalNAc-siRNA局部递送后在体内定位于视网膜,预防糖尿病诱导的视网膜病理改变,疗效与玻璃体腔注射相当。

临床怎么用

  • 局部滴眼递送GalNAc修饰的siHOTAIR可能成为糖尿病视网膜病变的非侵入性治疗选择,但需进一步开发验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Diabetic retinopathy (DR), a major cause of blindness in working-age adults, is driven by vascular dysfunction mediated by various angiogenic regulators. Although anti-VEGF therapies reduce vision impairment in some patients, they have limitations that leave room for novel treatments. The long non-coding RNA (lncRNA) HOX transcript antisense intergenic RNA (HOTAIR), which is upregulated in the retina in diabetes and regulates a range of factors including VEGF, contributes to DR pathology. Silencing HOTAIR prevents the dysregulation of VEGF and other factors. We explored targeting HOTAIR using siRNA conjugated to n-acetylgalactosamine (GalNAc) moieties for retinal delivery as a means of preventing diabetes-associated pathology in the retina. METHODS: GalNAc-modified siHOTAIR was evaluated in human retinal endothelial cells in vitro and using various models in vivo. The effects of GalNAc-modified siHOTAIR were assessed on the RNA, protein, and functional levels. RESULTS: GalNAc-modified siHOTAIR effectively entered retinal endothelial cells in vitro, and inhibited glucose-induced endothelial dysfunction by blocking multiple factors, including VEGF-A. GalNAc-siRNA localized to the retina in vivo following topical delivery, and prevented diabetes-induced pathological retinal changes with efficacy comparable to intravitreal injection. CONCLUSIONS: GalNAc-modified siHOTAIR thus represents a potential therapeutic strategy that not only inhibits VEGF but also targets other pathogenic mediators regulated by HOTAIR, potentially offering broader efficacy than anti-VEGF monotherapy. Furthermore, it achieves this via noninvasive, topical delivery, circumventing the need for intravitreal injections required by current treatments. Thus, with further development, GalNAc-modified siHOTAIR may become an overall better approach to treating DR.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Wang E, Feng B, Chen S, et al. Silencing of lncRNA HOTAIR Using Eyedrops as a Potential Treatment for Diabetes-Associated Retinal Dysregulation and Dysfunction. Invest Ophthalmol Vis Sci. 2026. PMID: 41805097. doi:10.1167/iovs.67.1.24

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。